Nora Therapeutics Is Hoping To Teach An Old Dog New Tricks In Fertility
This article was originally published in The Pink Sheet Daily
Executive Summary
Having raised an $18 million Series B, Nora is continuing a Phase II trial of lead G-CSF candidate NT100 in IVF failure. But the biotech also has begun enrolling a second Phase II study in women with unexplained recurrent miscarriage.